Patents
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
01/2007
01/31/2007CN1297276C 5-amino-salicylic acid intercalation medicinal slow-release agent and production thereof
01/31/2007CN1297275C The use of an anti-allergy agent and a steroid to treat allergic rhinitis
01/31/2007CN1297274C Medical composition
01/31/2007CN1297273C Pyrroloquinoline containing composition for enriching zinc and reducing plumbum
01/31/2007CN1297271C Fat emulsion injection of bulleyaconitine A and its manufacturing method
01/31/2007CN1297270C Ophthalmic composition comprising ascomycin
01/31/2007CN1297267C Medicinal composition containing tanshinon II A sodium sulfonate and its quality control method
01/31/2007CN1297264C Loselofen sodium injection and its preparation
01/31/2007CN1297263C Calcium gluconate oral disintegrating tablet and its preparation process
01/31/2007CN1297261C Fatty acyl acetaldehyde transfusion preparation and its preparing method
01/31/2007CN1297260C Fatty acyl acetaldehyde powder projection and its preparing method
01/31/2007CN1297257C Tulobuterol containing pressure-sensitive adhesive, transdermal paster, and its preparing method and use
01/31/2007CN1297256C Oral drop pills for treating coronary disease and preparation method thereof
01/31/2007CN1297255C Dripping pills for treating high blood fat and its preparing method
01/31/2007CN1297254C Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof
01/31/2007CN1297253C Medicinal transferring system for intracephalic transference of medicine
01/31/2007CN1297252C Concentrated solution of non-foaming ammonium compounds and method of use
01/31/2007CN1297251C Hot pepper gel for treating rheumatism
01/30/2007US7171277 System and method for controlling the delivery of medication to a patient
01/30/2007US7171274 Method and apparatus for communicating between an ambulatory medical device and a control device via telemetry using randomized data
01/30/2007US7169892 Wherein the lipid is conjugated to the amino terminus of the peptide by a peptide bond and the water-soluble polymer is conjugated to the carboxy terminus of the peptide by a peptide bond; for use as colloidal carriers and the like of tissue-specific drug delivery systems
01/30/2007US7169819 A pharmaceutical formulation for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent (an alcohol) and a alkoxylate castor oil, capable of dispersing or dissolving the retinide; anticancer agent
01/30/2007US7169812 Insertion catheter into cerebrospinal fluid; administering drug, preparing an injectable composition comprising gabapentin and a pharmaceutically acceptable vehicle; andheating the injectable composition at greater than or equal to about 105 degrees C
01/30/2007US7169811 Composition based on ethyl ester of linoleic acid and triethyl ester of citric acid for topical use in the treatment of seborrhea and acne
01/30/2007US7169767 Ophthalmic compositions containing galactomannan polymers and borate
01/30/2007US7169755 Viscosity-enhancing agent to increase the residence time of the solution in the heating chamber thereby increasing the expulsion force of the solution from the handpiece
01/30/2007US7169754 Blood disorders; drug in aqueous solution
01/30/2007US7169450 Enrobed core
01/30/2007US7169434 Drying; extrusion; reducing power needed
01/30/2007US7169411 Composition for delivery of biological agents and methods for the preparation thereof
01/30/2007US7169410 Targeted liposomal drug delivery system
01/30/2007US7169409 Heating film or laminate of a transdermal delivery device which comprises a dispersion of liquid drug in a matrix immediately following film formation or lamination; maintaining heat; cooling
01/30/2007US7169408 Bandage composition containing phage associated lytic enzymes useful for treating dermatological infections
01/30/2007US7169406 Drug delivery; analgesics, antiinflammatory agents; contacting skin with hydrogel containing drugs
01/30/2007US7169405 chemonucleolysis agent in solid form such that, when the device is placed into the nucleus pulposus of the intervertebral disc, it releases the chemonucleoylysis agent into the nuclear disc tissue surrounding the device to proteolytically degrade the tissue
01/30/2007US7169401 Topical skin care composition containing refined peanut oil
01/30/2007US7169391 Oil in water emulsions; induction immunology response; antigens
01/30/2007US7169385 Solubilized CoQ-10 and carnitine
01/30/2007US7169381 Aqueous solution of polyoxyethylene glycol , ascorbic acid and electrolyte
01/30/2007US7169379 Cosmetics
01/30/2007US7169378 Delivery of opioids through an inhalation route
01/30/2007US7169318 Imbibed organic liquids, especially halogenated organics
01/30/2007US7168605 Biologically implantable structure adapted to fit within the body of a patient and in physical communication with its outer surface
01/30/2007US7168597 Aerosol metering valve
01/30/2007CA2411153C Method for preparing a composition
01/30/2007CA2302411C Improved method for preventing crystal formation in a scopolamine transdermal device
01/30/2007CA2252609C Polyol composition
01/30/2007CA2251002C Estradiol and progesterone-based medicament
01/30/2007CA2173042C Petroleum butter comprising an acyl lactylate salt
01/30/2007CA2163363C Stable suppository formulations effecting biovailability of .delta.9-thc
01/30/2007CA2132977C Crosslinked biocompatible encapsulation compositions and methods
01/25/2007WO2007011989A2 Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
01/25/2007WO2007011972A2 Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
01/25/2007WO2007011940A2 Sustained release of antiinfectives
01/25/2007WO2007011922A2 Bioelectro-osmotic engine fluid delivery device
01/25/2007WO2007011919A2 Dual membrane electro-osmotic fluid delivery device
01/25/2007WO2007011875A2 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
01/25/2007WO2007011764A2 Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
01/25/2007WO2007011743A2 Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
01/25/2007WO2007011707A2 Polymer coatings containing drug powder of controlled morphology
01/25/2007WO2007011586A1 Halloysite microtubule processes, structures, and compositions
01/25/2007WO2007011524A1 Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
01/25/2007WO2007011473A1 Modified release ticlopidine compositions
01/25/2007WO2007011385A2 Heat cured gel and method of making
01/25/2007WO2007011349A1 Novel granulation process and granulate produced therefrom
01/25/2007WO2007011171A1 Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
01/25/2007WO2007011139A1 Sustained-release tablet containing paroxetine hydrochloride and manufacturing method thereof
01/25/2007WO2007011131A1 Stable controlled-release pellet containing tolterodine
01/25/2007WO2007011125A1 Transdermal patch comprising paroxetine
01/25/2007WO2007011030A1 Device for inhalation of medicine
01/25/2007WO2007011018A1 Rapidly disintegratable oral tablet
01/25/2007WO2007010930A1 Drug-containing coated fine particle for intrabuccally disintegrating preparation and method of producing the same
01/25/2007WO2007010900A1 Percutaneous absorption patch with application position indicating function, and iontophoresis device
01/25/2007WO2007010847A1 Sustained release preparation
01/25/2007WO2007010846A1 Preparation having gastric residence capability
01/25/2007WO2007010501A2 A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
01/25/2007WO2007010430A2 Pharmaceutical composition for treating xerostomia
01/25/2007WO2007010396A2 Dry state coating process
01/25/2007WO2007010337A2 Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
01/25/2007WO2007010032A2 Intermolecular association complex of a carrier, preferably an n-alkylamino -1-desoxylactitol and of an active ingredient
01/25/2007WO2007009997A1 Composition containing micronutrients with improved anti-oxidant activity and the use thereof.
01/25/2007WO2007009806A2 Solid dosage formulations of narcotic drugs having improved buccal adsorption
01/25/2007WO2007009801A2 Oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug
01/25/2007WO2007009800A2 Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent
01/25/2007WO2007009683A2 Pharmaceutical formulations of substituted pyrazoline compounds
01/25/2007WO2007009404A1 Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system
01/25/2007WO2007009383A1 A rectum suppository of protein and its preparation method and the use
01/25/2007WO2007009382A1 Use of rhgm-csf for the manufacturing of an external medicament for the treatment of cervicitis and/or cervical erosion
01/25/2007WO2007009355A1 Paclitaxel injection and preparation method thereof
01/25/2007WO2007009320A1 A preparation of statins for prolonged release
01/25/2007WO2007009200A2 Process for nanocomposites preparation, and nanocomposites
01/25/2007WO2006130702A3 Modified release formulations of antihypertensive drugs
01/25/2007WO2006129320A3 Biodegradable polymers having a pre-determined chirality
01/25/2007WO2006125642B1 Methods and apparatus for transdermal or transmucosal application of testosterone
01/25/2007WO2006125123A3 Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
01/25/2007WO2006124366A3 Flavoring of drug-containing chewing gums
01/25/2007WO2006117803A3 Transmucosal drug delivery systems
01/25/2007WO2006117516A3 Topical compositions
01/25/2007WO2006109317A8 A process for the preparation of poly dl-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein
01/25/2007WO2006102494A3 Nanoparticulate corticosteroid and antihistamine formulations